Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin’s lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study

[1] Dulisse B(2013)A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia J Med Econ 16 720-735

[2] Li X(2006)Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258-2266

[3] Gayle JA(2010)Risk of mortality in patients with cancer who experience febrile neutropenia Cancer 116 5555-5563

[4] Barron RL(2015)Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors J Oncol Pract 11 47-54

[5] Ernst FR(2011)Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma Crit Rev Oncol Hematol 77 221-240

[6] Rothman KJ(2007)Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim Oncologist 12 1416-1424

[7] Legg JC(2010)A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy Clin Colorectal Cancer 9 95-101

[8] Kaye JA(2005)First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study J Clin Oncol 23 1178-1184

[9] Kuderer NM(2007)Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol 25 3158-3167

[10] Dale DC(1988)Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium N Engl J Med 318 1414-1422

[1] Dulisse B(2013)A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia J Med Econ 16 720-735

[2] Li X(2006)Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258-2266

[3] Gayle JA(2010)Risk of mortality in patients with cancer who experience febrile neutropenia Cancer 116 5555-5563

[4] Barron RL(2015)Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors J Oncol Pract 11 47-54

[5] Ernst FR(2011)Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma Crit Rev Oncol Hematol 77 221-240

[6] Rothman KJ(2007)Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim Oncologist 12 1416-1424

[7] Legg JC(2010)A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy Clin Colorectal Cancer 9 95-101

[8] Kaye JA(2005)First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study J Clin Oncol 23 1178-1184

[9] Kuderer NM(2007)Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review J Clin Oncol 25 3158-3167

[10] Dale DC(1988)Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium N Engl J Med 318 1414-1422